echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > The results of two Phase 3 clinical trials of dual-mechanism diabetes therapy were positive

    The results of two Phase 3 clinical trials of dual-mechanism diabetes therapy were positive

    • Last Update: 2021-02-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Tirzepatide, one of Lilly's highly-expected development projects, is a weekly injection of GIP and GLP-1-1-like dual exciters that integrate the effects of two types of intestinal insulin into a molecule representing a new approach to the treatment of type 2 diabetes.
    GIP is a hormone that may supplement the role of GLP-1 subjectors.
    In preclinical models, GIP has been shown to reduce intake and increase energy consumption, resulting in weight loss, which, when used in union with GLP-1 vector agonists, may have a greater impact on glucose levels and weight.
    has launched a series of Phase 3 clinical trials to test the effectiveness of tirzepatide as a single-drug therapy or in combination with other therapies to treat different types of type 2 diabetes patients.
    , tirzepatide's Phase 3 clinical trials for the treatment of obesity and Phase 2 clinical trials for the treatment of non-alcoholic fatty hepatitis (NASH) are also under way.
    in a randomized, open-label clinical trial called SURFASS-3, patients with type 2 diabetes with type 2 diabetes who did not have effective control of their blood sugar received different doses of tirzepatide or long-acting insulin-like inclin deudec after receiving metformin (including or not containing an SGLT2 inhibitor).
    patients had an average diabetes history of 8.4 years and had not received insulin treatment.
    results showed that after 52 weeks of treatment, all doses of tirzepatide resulted in more significant A1C levels and weight loss than the active control group.
    Among patients treated with the highest dose of tirzepatide, 92.6 percent had A1C levels less than 7 percent (the American Diabetes Association recommended that diabetics achieve levels) and 48.4 percent had A1C levels less than 5.7 percent (healthy people with A1C levels). data on the efficacy of
    Tirzepatide in the SURPASS-3 clinical trial (Photo Source: Reference 1) In a randomized double-blind clinical trial called SURPASS-5, type 2 diabetics who had been treated with insulin glargine received insulin glargine in addition to insulin glavine for treatment with tirzepatide or placebo.
    had an average diabetes history of 13.3 years.
    in this clinical trial, Tirzepatide also reached all major and critical secondary endpoints.
    of patients treated with the highest dose of tirzepatide, 62.4% had A1C levels of less than 5.7%, reaching healthy levels, and their weight was 10.9 kg (11.6%) lower than the baseline. "For people with type 2 diabetes who need to start injecting therapy, these positive results demonstrate the potential for tirzepatide to significantly reduce A1C and body weight," said
    Tirzepatide's efficacy data in the SURPASS-5 clinical trial (Photo Source: Reference.
    ," said Dr. Bernhard Ludvik, a professor of medicine at the Landstrasse Clinic in Vienna and lead researcher in the SURPASS-3 clinical trial.
    : This article is intended to introduce medical and health research, not treatment options recommended.
    if you need guidance on treatment options, visit a regular hospital.
    resources: sirzepatide greatly reduced A1C and body weight in people with type 2 diabetes in two phase 3 trials from Lilly's SURPASS program. Retrieved February 17, 2021, from [2] Tirzepatide SURPASS Phase 3 program overview.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.